Beijing Tiantan Biological Products Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Beijing Tiantan Biological Products de 18.2% y 18.2% por año respectivamente. Se prevé que el BPA crezca en un 18.9% al año. Se espera que la rentabilidad financiera sea de 13.1% en 3 años.

Información clave

18.0%

Tasa de crecimiento de los beneficios

19.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	38.4%
Tasa de crecimiento de los ingresos	18.3%
Rentabilidad financiera futura	13.7%
Cobertura de analistas	Good
Última actualización	19 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Sep 19

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01

Previsiones de crecimiento de beneficios e ingresos

SHSE:600161 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	8,490	1,975	1,820	2,630	10
12/31/2025	7,215	1,648	1,589	2,306	10
12/31/2024	6,131	1,379	1,082	1,270	7
6/30/2024	5,331	1,269	1,183	2,328	N/A
3/31/2024	5,110	1,165	1,087	2,242	N/A
12/31/2023	5,180	1,110	1,316	2,394	N/A
9/30/2023	5,371	1,167	1,254	2,515	N/A
6/30/2023	5,062	1,063	341	1,633	N/A
3/31/2023	4,848	1,018	250	1,539	N/A
12/31/2022	4,261	881	-228	1,126	N/A
9/30/2022	4,207	803	-195	1,097	N/A
6/30/2022	4,191	808	-187	1,117	N/A
3/31/2022	3,970	733	-351	918	N/A
12/31/2021	4,112	760	-151	980	N/A
9/30/2021	3,628	700	-241	728	N/A
6/30/2021	3,702	692	-120	640	N/A
3/31/2021	3,535	659	-71	571	N/A
12/31/2020	3,446	639	93	702	N/A
9/30/2020	3,398	641	306	755	N/A
6/30/2020	3,276	601	362	877	N/A
3/31/2020	3,334	611	184	741	N/A
12/31/2019	3,282	611	116	642	N/A
9/30/2019	3,394	580	282	788	N/A
6/30/2019	3,271	563	376	801	N/A
3/31/2019	3,083	531	729	1,028	N/A
12/31/2018	2,931	509	384	678	N/A
9/30/2018	2,929	568	538	767	N/A
6/30/2018	2,671	532	398	590	N/A
3/31/2018	2,485	1,228	N/A	186	N/A
12/31/2017	2,483	1,173	N/A	138	N/A
9/30/2017	2,362	1,077	N/A	301	N/A
6/30/2017	2,256	1,038	N/A	280	N/A
3/31/2017	2,330	313	N/A	344	N/A
12/31/2016	2,138	257	N/A	433	N/A
9/30/2016	1,756	151	N/A	251	N/A
6/30/2016	1,709	55	N/A	403	N/A
3/31/2016	1,624	-3	N/A	471	N/A
12/31/2015	1,618	10	N/A	473	N/A
9/30/2015	1,545	-88	N/A	384	N/A
6/30/2015	1,567	-46	N/A	382	N/A
3/31/2015	1,723	46	N/A	560	N/A
12/31/2014	1,827	128	N/A	478	N/A
9/30/2014	2,026	291	N/A	748	N/A
6/30/2014	2,018	377	N/A	705	N/A
3/31/2014	1,905	371	N/A	490	N/A
12/31/2013	1,837	372	N/A	566	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.2% al año) de 600161 es superior a la tasa de ahorro (2.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (18.3% al año) de 600161 crezcan menos que el mercado CN (24.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 600161 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (18.2% al año) de 600161 crezcan más rápidamente que los del mercado CN (13.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 18.2% al año) de 600161 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 600161 sea baja dentro de 3 años (13.1%).

Beijing Tiantan Biological Products Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 11% to CN¥33.90

Recent updates

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 23%

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Second quarter 2024 earnings: EPS misses analyst expectations

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 20%

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Price target increased by 11% to CN¥33.90

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Now 27% overvalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd., Annual General Meeting, May 29, 2024

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.53 in FY 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.075 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from S&P Global BMI Index

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from FTSE All-World Index (USD)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2021)

Now 20% undervalued

Now 21% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 1Q 2020)

New 90-day low: CN¥36.46

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.50

New 90-day high: CN¥41.95

Beijing Tiantan Biological Products Co., Ltd. announced that it expects to receive CNY 3.34 billion in funding

Third quarter earnings released

New 90-day low: CN¥37.99

First half earnings released

First half earnings released

New 90-day high - CN¥42.80

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento